Evidence map›Paper›PMID 40064701›Full record

ArticleACS applied materials & interfaces2025

Platelet Membrane and miR-181a-5p Doubly Optimized Nanovesicles Enhance Cardiac Repair Post-Myocardial Infarction through Macrophage Polarization.

Dongyue Liu, Xianyun Wang, Zhao Liu, Lini Ding, Mei Liu, Tianshuo Li, Shasha Zeng, Mingqi Zheng, Le Wang, Jun Zhang and 4 more

Abstract read
In one paragraph

Article in ACS applied materials & interfaces, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Biomimetic Cell Membrane-Coated Scaffolds for Enhanced Tissue Regeneration.Advanced materials (Deerfield Beach, Fla.) · 2025
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dongyue LiuDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.ORCID 0000-0001-7275-4985
Xianyun WangDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.ORCID 0000-0003-2224-4770
Zhao LiuTraditional Chinese Medicine Processing Technology Innovation Center of Hebei Province, School of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang 050091, China.
Lini DingDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Mei LiuDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Tianshuo LiDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Shasha ZengDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Mingqi ZhengDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Le WangDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Jun ZhangDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Fan ZhangDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Meng LiCollege of Pharmacy, Key Laboratory of Innovative Drug Development and Evaluation, Hebei Medical University, Shijiazhuang 050017, China.ORCID 0000-0002-8348-6768
Gang LiuDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.
Yida TangDepartment of Cardiovascular Medicine, The First Hospital of HeBei Medical University, Shijiazhuang 050031, Hebei Province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages play a crucial role in cardiac remodeling and prognosis after myocardial infarction (MI). Our previous studies have built a scalable method for preparing scaled stem cell nanovesicles (NVs) and demonstrated their remarkable reparative effects on ischemic heart disease. To further enhance the targeted reparative capabilities of the NVs toward injured myocardium, we employed a dual modification strategy involving platelet membrane coating and miR-181a-5p loading, creating a nanovesicle termed P-181-NV. This study aimed to investigate the efficacy of P-181-NV in targeted reparative interventions for damaged myocardium and to reveal the underlying mechanisms involved. After successful construction and characteristic analysis of P-181-NV, the

Indexed as

Blood PlateletsMacrophagesMicroRNAsMyocardial InfarctionAnimalsCell SurvivalHumansMaleMiceMice, Inbred C57BLMyocardiumMicroRNAsmirn181 microRNA, mouseanti-inflammatory effectcardiac repairmacrophage polarizationMiR-181a-5p loaded nanovesiclesplatelet membrane modification

Identifiers

PMID40064701
PMCPMC11931480

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.